NeoGenomics, Inc.

DB:NG9 Stock Report

Market Cap: €2.1b

NeoGenomics Valuation

Is NG9 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NG9 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NG9 (€15.8) is trading below our estimate of fair value (€84.57)

Significantly Below Fair Value: NG9 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NG9?

Key metric: As NG9 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NG9. This is calculated by dividing NG9's market cap by their current revenue.
What is NG9's PS Ratio?
PS Ratio3.3x
SalesUS$644.12m
Market CapUS$2.12b

Price to Sales Ratio vs Peers

How does NG9's PS Ratio compare to its peers?

The above table shows the PS ratio for NG9 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.8x
SYAB SYNLAB
0.9x4.4%€2.5b
FME Fresenius Medical Care
0.7x3.9%€12.8b
FRE Fresenius SE KGaA
0.8x3.7%€18.9b
V3V VITA 34
0.9x3.1%€73.6m
NG9 NeoGenomics
3.3x10.8%€2.1b

Price-To-Sales vs Peers: NG9 is expensive based on its Price-To-Sales Ratio (3.3x) compared to the peer average (0.8x).

Price to Sales Ratio vs Industry

How does NG9's PS Ratio compare vs other companies in the DE Healthcare Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
EIF MedNation
0.09xn/aUS$4.65m
TLIK Arzneiwerk VIDA
0.07xn/aUS$4.28m
No more companies available in this PS range
NG9 3.3xIndustry Avg. 0.7xNo. of Companies4PS00.40.81.21.62+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: NG9 is expensive based on its Price-To-Sales Ratio (3.3x) compared to the European Healthcare industry average (0.7x).

Price to Sales Ratio vs Fair Ratio

What is NG9's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NG9 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.3x
Fair PS Ratio1.7x

Price-To-Sales vs Fair Ratio: NG9 is expensive based on its Price-To-Sales Ratio (3.3x) compared to the estimated Fair Price-To-Sales Ratio (1.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NG9 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€15.80
€20.09
+27.1%
16.1%€28.58€17.15n/a12
Dec ’25€16.70
€19.63
+17.5%
17.2%€28.16€16.89n/a11
Nov ’25€12.50
€19.31
+54.5%
17.2%€27.71€16.62n/a11
Oct ’25€13.10
€19.03
+45.3%
16.8%€26.96€16.17n/a11
Sep ’25€14.70
€19.33
+31.5%
16.8%€27.38€16.43n/a11
Aug ’25€16.30
€19.48
+19.5%
17.0%€27.71€16.62n/a11
Jul ’25€12.80
€19.07
+49.0%
16.1%€26.10€15.85n/a11
Jun ’25€12.90
€19.07
+47.8%
16.1%€26.10€15.85n/a11
May ’25€14.70
€19.30
+31.3%
16.3%€26.19€15.90n/a11
Apr ’25€14.00
€19.86
+41.8%
17.1%€27.65€16.59n/a11
Mar ’25€14.40
€19.86
+37.9%
17.1%€27.65€16.59n/a11
Feb ’25€14.50
€18.55
+27.9%
15.4%€24.01€15.70n/a11
Jan ’25€15.30
€18.20
+18.9%
15.4%€23.55€15.40€15.9011
Dec ’24€16.60
€19.61
+18.1%
20.2%€28.01€14.94€16.7011
Nov ’24€13.20
€19.05
+44.3%
18.8%€24.55€14.16€12.5011
Oct ’24€11.80
€19.30
+63.5%
15.0%€23.69€15.49€13.1011
Sep ’24€13.80
€19.30
+39.8%
15.0%€23.69€15.49€14.7011
Aug ’24€15.70
€19.56
+24.6%
12.7%€23.50€15.37€16.3011
Jul ’24€14.60
€20.18
+38.2%
14.5%€25.79€15.66€12.8011
Jun ’24€16.00
€20.18
+26.1%
14.5%€25.79€15.66€12.9011
May ’24€12.90
€18.41
+42.7%
14.2%€23.83€15.58€14.7011
Apr ’24€15.96
€18.98
+18.9%
13.7%€24.45€15.99€14.0011
Mar ’24€15.72
€18.96
+20.6%
14.1%€24.65€16.11€14.4011
Feb ’24€11.53
€14.29
+24.0%
27.2%€23.67€9.10€14.5010
Jan ’24€8.73
€15.59
+78.6%
27.7%€25.16€9.68€15.309

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 10:51
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NeoGenomics, Inc. is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruce JacksonBenchmark Company
Raymond MyersBenchmark Company
Derik de BruinBofA Global Research